Reach - Non-Regulatory
2 October 2023
N4 Pharma Plc
("N4 Pharma" or the "Company")
Investor Presentation
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that an updated investor presentation ("Presentation") incorporating the Company's acquisition of a 71% interest in Nanogencis Limited is now available on the N4 Pharma website. To view a copy of the Presentation, please click here: http://www.rns-pdf.londonstockexchange.com/rns/2596O_1-2023-10-1.pdf
Enquiries:
|
N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director |
Via IFC Advisory |
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker IFC Advisory Limited Financial PR Graham Herring Zach Cohen |
Tel: +44 (0)20 3657 0050 Tel: +44 (0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.